Estimated Annual Spending on Aducanumab in the US Medicare Program.

ABSTRACT: This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

SUBMITTER: Mafi JN 

PROVIDER: S-EPMC8903103 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature